What Portec 3?
Background. The PORTEC-3 trial investigated the benefit of combined adjuvant chemotherapy and radiotherapy versus pelvic radiotherapy alone for women with high-risk endometrial cancer. We updated the analysis to investigate patterns of recurrence and did a post-hoc survival analysis.
What does Portec stand for?
The international randomized Adjuvant Chemoradiotherapy Versus Radiotherapy Alone in Women with High-Risk Endometrial Cancer (PORTEC-3) trial investigated the benefit of adjuvant chemotherapy in combination with EBRT (chemoradiotherapy (CTRT)) versus EBRT alone (radiotherapy (RT)) in patients with high-risk EC [2].
Should grade 3 endometrioid endometrial carcinoma be considered a type 2 cancer a clinical and pathological evaluation?
Grade 3 endometrioid cancers (G3 EEC), share features of type 1 and type 2 cancer and have not been classified as either.
Can Stage 1a endometrial cancer be cured?
Stage I uterine cancer is curable with surgery alone for the majority of patients.
What is vaginal brachytherapy VBT?
Surgery is the radical curative method. Adjuvant radiotherapy is recommended for specific patient subgroups. The radiation modality consists of pelvic external beam radiotherapy (EBRT) to the pelvis and vaginal brachytherapy (VBT) to the vaginal cuff to clear up microscopic disease in the locoregional area.
What is the survival rate for stage 3 endometrial cancer?
58% for women with stage IIIA. 50% for women with stage IIIB. 47% for women with stage IIIC.
What is adjuvant vaginal brachytherapy?
Adjuvant vaginal brachytherapy with a low dose regimen results in excellent clinical outcomes for patients with early stage endometrial cancer. Patients with higher BMI and cervical extension may be at increased risk of VR, and additional study is needed to determine optimal brachytherapy treatment parameters.
What is introduced into the body for brachytherapy?
Radiation inserted into body tissue. During interstitial brachytherapy, devices containing radioactive material are placed within body tissue, such as within the breast or prostate. Devices that deliver interstitial radiation into the treatment area include wires, balloons and tiny seeds the size of grains of rice.
How does brachytherapy relate with the electromagnetic waves?
Brachytherapy, also called internal radiation therapy, places radioactive material directly inside or next to the tumor. It uses a higher total dose of radiation to treat a smaller area than external beam radiation therapy (EBRT) which directs high-energy x-ray beams at a tumor from outside the body.
Is high grade serous carcinoma curable?
Is high-grade serous ovarian carcinoma curable? Patients with HGSOC often respond well to treatment, and can experience remission — however, it is common for high-grade serous patients to recur over a period of time, with the majority of recurrences occurring within three years.
What are the chances of dying from endometrial cancer?
5-year relative survival rates for endometrial cancer
| SEER Stage | 5-year Relative Survival Rate |
|---|---|
| Localized | 96% |
| Regional | 71% |
| Distant | 20% |
| All SEER stages combined | 84% |
What is the portec-3 trial?
The PORTEC-3 trial was initiated to investigate the benefit of adjuvant chemotherapy during and after radiotherapy (chemoradiotherapy) versus pelvic radiotherapy alone for women with high-risk endometrial cancer.
What does portec-1 stand for?
Purpose: To evaluate the very long-term results of the randomized Post Operative Radiation Therapy in Endometrial Carcinoma (PORTEC)-1 trial for patients with Stage I endometrial carcinoma (EC), focusing on the role of prognostic factors for treatment selection and the long-term risk of second cancers.
What do the 15-year outcomes of portec-1 tell us about EBRT?
Conclusions: The 15-year outcomes of PORTEC-1 confirm the relevance of HIR criteria for treatment selection, and a trend for long-term risk of second cancers. EBRT should be avoided in patients with low- and intermediate-risk EC. Copyright © 2011 Elsevier Inc.
What is the role of radiotherapy in the portec-3 study?
In PORTEC-3 study, the patients with high-risk disease were randomly assigned to receive pelvic radiotherapy alone or the combination of radiotherapy with two cycles of concurrent cisplatin followed by four cycles of adjuvant paclitaxel/carboplatin. The study co-primary endpoints were OS and FFS.